Bladder Cancer Weekly

May 04, 2026

Videos

Peer-to-Peer Clinical Conversations

Surgical Management of NMIBC: Comparing En Bloc to Standard Resection Techniques - Jeremy Teoh

Jeremy Yuen Chun Teoh

Jeremy Teoh describes a randomized trial of en bloc versus conventional TURBT.

Subgroup Findings from CREST Trial in High-Risk Bladder Cancer - Gary Steinberg

Gary Steinberg discusses CREST trial subgroup analysis of very high-risk BCG-naive NMIBC.

Beyond the Abstracts

A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity - Beyond the Abstract

Modulating the PPARγ Pathway Upregulates NECTIN4 and Enhances Chimeric Antigen Receptor (CAR) T Cell Therapy in Bladder Cancer - Beyond the Abstract

Conference Coverage

SES AUA 2026: Response to Treatment with UGN-102 in Patients with Early or Late Recurrent Low-Grade Intermediate Risk NMIBC

SES AUA 2026: Implementation of Patient Reported Outcomes as a NMIBC Clinical Trial Endpoint

EAU 2026: Trial Highlights: CREST — Sasanlimab + BCG (Positive)

EAU 2026: Trial Highlights: ALBAN - Atezolizumab + BCG (Negative)

ASCO GU 2026: A Phase III Randomized Control Clinical Trial of Radiotherapy with Radiosensitization Versus Intravesical BCG Therapy for High-Risk NMIBC: TRAIN

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Extent of Pelvic Lymph Node Dissection at Partial Cystectomy: Effect on Cancer-Specific Mortality.

The role of HAI-1 in urothelial bladder cancer: Tissue expression, ectodomain shedding and clinical outcomes.

Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2EV project.

Association Between Proto-Oncogene N-RAS Transcript Level and Overall Survival in Node-Negative Muscle-Invasive Bladder Cancer.

Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study.

Bayesian reanalysis of the NIAGARA trial using reconstructed individual patient data: perioperative durvalumab in cisplatin-eligible muscle-invasive bladder cancer.

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Tria

Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.

Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions.

Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette-Guérin immunotherapy.

Evolution of survival outcomes in robot-assisted radical cystectomy over 20 years of experience in a high-volume tertiary robotic center.

Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial.

Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.

Circulating tumor DNA as a prognostic and monitoring biomarker in urothelial cancers.

Prognostic Factors and Oncological Outcomes after Trimodality Bladder-Preserving Therapy for Muscle-Invasive Bladder Cancer: A Multicenter Real-World Study - Read the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC